DE60010323T2 - Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung - Google Patents
Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung Download PDFInfo
- Publication number
- DE60010323T2 DE60010323T2 DE60010323T DE60010323T DE60010323T2 DE 60010323 T2 DE60010323 T2 DE 60010323T2 DE 60010323 T DE60010323 T DE 60010323T DE 60010323 T DE60010323 T DE 60010323T DE 60010323 T2 DE60010323 T2 DE 60010323T2
- Authority
- DE
- Germany
- Prior art keywords
- target species
- test
- test compound
- denaturing conditions
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 73
- 238000004925 denaturation Methods 0.000 claims abstract description 64
- 230000036425 denaturation Effects 0.000 claims abstract description 64
- 238000012360 testing method Methods 0.000 claims abstract description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 238000009792 diffusion process Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 230000008859 change Effects 0.000 claims abstract description 13
- 241000894007 species Species 0.000 claims description 72
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 238000013537 high throughput screening Methods 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 235000012308 Tagetes Nutrition 0.000 claims 3
- 241000736851 Tagetes Species 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 52
- 239000003446 ligand Substances 0.000 description 22
- 238000000113 differential scanning calorimetry Methods 0.000 description 18
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
- 238000012036 ultra high throughput screening Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000007704 transition Effects 0.000 description 6
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 229960000838 tipranavir Drugs 0.000 description 5
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000006862 quantum yield reaction Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- YDLYQMBWCWFRAI-UHFFFAOYSA-N hexatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 description 1
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000005311 autocorrelation function Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/12—Condition responsive control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/13—Tracers or tags
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/458,172 US6582907B1 (en) | 1999-12-09 | 1999-12-09 | Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions |
| US458172 | 1999-12-09 | ||
| PCT/US2000/042642 WO2001044817A2 (en) | 1999-12-09 | 2000-12-07 | Fluorescence correlation spectroscopy to identify compound-target binding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60010323D1 DE60010323D1 (de) | 2004-06-03 |
| DE60010323T2 true DE60010323T2 (de) | 2005-05-25 |
Family
ID=23819671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60010323T Expired - Fee Related DE60010323T2 (de) | 1999-12-09 | 2000-12-07 | Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6582907B1 (enExample) |
| EP (1) | EP1236047B1 (enExample) |
| JP (1) | JP2003517609A (enExample) |
| AT (1) | ATE265684T1 (enExample) |
| AU (1) | AU777163B2 (enExample) |
| CA (1) | CA2392239A1 (enExample) |
| DE (1) | DE60010323T2 (enExample) |
| DK (1) | DK1236047T3 (enExample) |
| ES (1) | ES2218280T3 (enExample) |
| HK (1) | HK1047158B (enExample) |
| PT (1) | PT1236047E (enExample) |
| TR (1) | TR200401075T4 (enExample) |
| WO (1) | WO2001044817A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
| US6517781B1 (en) * | 1997-06-02 | 2003-02-11 | Aurora Biosciences Corporation | Low fluorescence assay platforms and related methods for drug discovery |
| DE10013854A1 (de) * | 2000-03-17 | 2001-09-20 | Zeiss Carl Jena Gmbh | Anordnung und Verfahren zur Untersuchung von Wirkstoffen zur Beeinflussung intrazellulärer Vorgänge |
| AU2003202026A1 (en) | 2002-01-16 | 2003-09-02 | Dynal Biotech Asa | Method for isolating nucleic acids and protein from a single sample |
| CN1662810A (zh) | 2002-06-21 | 2005-08-31 | 奥林巴斯株式会社 | 生物分子分析装置 |
| AU2003259056B2 (en) * | 2002-08-01 | 2007-10-04 | Sensor Technologies Llc | Method of measuring molecular interactions |
| GB0229287D0 (en) * | 2002-12-16 | 2003-01-22 | Dna Res Innovations Ltd | Polyfunctional reagents |
| WO2006013109A1 (en) * | 2004-08-06 | 2006-02-09 | Epfl Swiss Federal Institute Of Technology-Lausanne | Method for testing a substance interacting with a target molecule |
| WO2006087727A1 (en) * | 2005-02-15 | 2006-08-24 | Tata Institute Of Fundamental Research | Fluorescence correlation microscopy with real-time alignment readout |
| DE102007045666A1 (de) * | 2007-09-25 | 2009-04-02 | Carl Zeiss Microimaging Gmbh | Verfahren und Anordnung zur Ausgabe von Restfehlern einer an eine Punktemenge angepassten Funktion |
| KR100963305B1 (ko) | 2008-01-23 | 2010-06-11 | 건국대학교 산학협력단 | 단백질 내의 도메인 간 변성과정 분석방법 |
| US12400741B2 (en) * | 2020-02-28 | 2025-08-26 | Howard University | Selective extraction of late exponentials |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5679582A (en) | 1993-06-21 | 1997-10-21 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| CA2184195C (en) | 1995-10-25 | 2002-04-16 | Andrew Pakula | Screening method for identifying ligands for target proteins |
| JP2000502440A (ja) | 1995-12-07 | 2000-02-29 | スクリプトジェン・ファーマスーティカルズ，インコーポレイテッド | リガンドを識別するための蛍光に基づくスクリーニング方法 |
| KR20000011069A (ko) | 1996-05-09 | 2000-02-25 | 스리-디멘셔널 파마슈티컬스 인코포레이티드 | 리간드 개발 및 다변수 단백질 화학의 최적화를 위한미량이식판 열 이동 분석 및 그 장치 |
| EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
| CA2306686A1 (en) | 1997-12-05 | 1999-06-17 | Pharmacia & Upjohn Company | Fluorescence-based high throughput screening assays for protein kinases and phosphatases |
| US6242190B1 (en) | 1999-12-01 | 2001-06-05 | John Hopkins University | Method for high throughput thermodynamic screening of ligands |
| US6376180B1 (en) * | 1999-12-09 | 2002-04-23 | Pharmacia & Upjohn Company | Methods of identifying compounds that bind to target species under isothermal denaturing conditions |
-
1999
- 1999-12-09 US US09/458,172 patent/US6582907B1/en not_active Expired - Fee Related
-
2000
- 2000-12-07 PT PT00992663T patent/PT1236047E/pt unknown
- 2000-12-07 TR TR2004/01075T patent/TR200401075T4/xx unknown
- 2000-12-07 EP EP00992663A patent/EP1236047B1/en not_active Expired - Lifetime
- 2000-12-07 DK DK00992663T patent/DK1236047T3/da active
- 2000-12-07 HK HK02108073.1A patent/HK1047158B/en not_active IP Right Cessation
- 2000-12-07 ES ES00992663T patent/ES2218280T3/es not_active Expired - Lifetime
- 2000-12-07 AU AU45198/01A patent/AU777163B2/en not_active Ceased
- 2000-12-07 AT AT00992663T patent/ATE265684T1/de not_active IP Right Cessation
- 2000-12-07 WO PCT/US2000/042642 patent/WO2001044817A2/en not_active Ceased
- 2000-12-07 JP JP2001545854A patent/JP2003517609A/ja active Pending
- 2000-12-07 CA CA002392239A patent/CA2392239A1/en not_active Abandoned
- 2000-12-07 DE DE60010323T patent/DE60010323T2/de not_active Expired - Fee Related
-
2003
- 2003-05-27 US US10/445,513 patent/US20030219820A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001044817A2 (en) | 2001-06-21 |
| CA2392239A1 (en) | 2001-06-21 |
| TR200401075T4 (tr) | 2004-07-21 |
| HK1047158B (en) | 2004-12-03 |
| DK1236047T3 (da) | 2004-07-05 |
| PT1236047E (pt) | 2004-08-31 |
| AU4519801A (en) | 2001-06-25 |
| HK1047158A1 (en) | 2003-02-07 |
| EP1236047B1 (en) | 2004-04-28 |
| US6582907B1 (en) | 2003-06-24 |
| ES2218280T3 (es) | 2004-11-16 |
| ATE265684T1 (de) | 2004-05-15 |
| WO2001044817A3 (en) | 2002-05-10 |
| EP1236047A2 (en) | 2002-09-04 |
| DE60010323D1 (de) | 2004-06-03 |
| JP2003517609A (ja) | 2003-05-27 |
| AU777163B2 (en) | 2004-10-07 |
| US20030219820A1 (en) | 2003-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69722800T2 (de) | Probenanalyseverfahren mittels bestimmung einer funktion der spezifischen helligkeit | |
| DE60010323T2 (de) | Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung | |
| DE69624942T2 (de) | Screening von natürlichen proben für neue therapeutische verbindungen mittels kapillarelectrophorese | |
| DE69218002T2 (de) | Differentialtrennungs-Analyse | |
| Bradley et al. | pH sensing in living cells using fluorescent microspheres | |
| Hink et al. | Imaging protein-protein interactions in living cells | |
| DE60038127T2 (de) | Methoden und syteme zur überwachung intrazellulärer bindereaktionen | |
| Gough et al. | Fluorescence anisotropy imaging microscopy maps calmodulin binding during cellular contraction and locomotion. | |
| DE2953524C2 (enExample) | ||
| US6713260B2 (en) | Methods of identifying compounds that bind to target species under isothermal denaturing conditions | |
| EP1295124B1 (de) | Kompetitives assay-verfahren | |
| EP1024363A2 (de) | Quantitative Bestimmung von Analyten in einem heterogenen System | |
| EP0920625B1 (de) | Verfahren zum wirkstoff-screening | |
| DE69626639T2 (de) | Phycobilisome, derivate und ihre verwendung | |
| WO2000075657A2 (de) | Screening von target-ligand-wechselwirkungen | |
| DE102018126183B4 (de) | Verfahren zur Bestimmung der Konzentration eines fluoreszierenden und/oder fluoreszenzmarkierten Analyten und Kalibrierverfahren zur Vorbereitung dieser Bestimmung | |
| EP3454063B1 (de) | Durchflusszytometrie-messverfahren | |
| EP2122364B1 (de) | Verfahren zur identifizierung der agonistischen aktivität einer zielverbindung auf einen kaliumkanal | |
| EP1327886B1 (de) | Verfahren zum Nachweis von Analyten in Proben mittels Analysenelementen | |
| Lakowicz et al. | Fluorescence lifetime imaging of Ca2+ using visible wavelength excitation and emission | |
| EP1521964B1 (de) | Verfahren zur bestimmung der zahl von rezeptoren auf einem träger | |
| DE10202482B4 (de) | Molekularer Sensorkomplex, Messsondenanordnung und Verfahren zur pharmakologischen Wirkstoff- und/oder Wirkorttestung | |
| Denksteinová et al. | Three fluorescent probes for the flow-cytometric assessment of membrane potential in Saccharomyces cerevisiœ | |
| Suku et al. | Micelle-Assisted Early Detection of Brodifacoum with Investigations into Serum Protein Binding and Bioavailability | |
| Carter-SuS et al. | M, zyxwvutsrqponmlk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |